Fox Run Management L.L.C. Raises Stock Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)

Fox Run Management L.L.C. raised its holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 199.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 48,950 shares of the biopharmaceutical company's stock after acquiring an additional 32,579 shares during the quarter. Fox Run Management L.L.C. owned 0.08% of Sage Therapeutics worth $266,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in the stock. Picton Mahoney Asset Management lifted its stake in shares of Sage Therapeutics by 126.0% in the fourth quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company's stock valued at $35,000 after purchasing an additional 3,581 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in shares of Sage Therapeutics during the 4th quarter valued at approximately $49,000. Ieq Capital LLC purchased a new stake in shares of Sage Therapeutics during the 4th quarter worth approximately $57,000. US Bancorp DE grew its holdings in shares of Sage Therapeutics by 22.3% in the 4th quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company's stock worth $67,000 after acquiring an additional 2,268 shares during the period. Finally, Teacher Retirement System of Texas grew its holdings in shares of Sage Therapeutics by 21.6% in the 4th quarter. Teacher Retirement System of Texas now owns 13,768 shares of the biopharmaceutical company's stock worth $75,000 after acquiring an additional 2,446 shares during the period. 99.22% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Sage Therapeutics Trading Down 1.0 %

Shares of SAGE traded down $0.08 during mid-day trading on Tuesday, reaching $7.87. The company had a trading volume of 240,504 shares, compared to its average volume of 1,218,950. The stock has a market cap of $483.92 million, a price-to-earnings ratio of -1.19 and a beta of 0.82. The firm has a fifty day simple moving average of $7.49 and a 200-day simple moving average of $6.73. Sage Therapeutics, Inc. has a fifty-two week low of $4.62 and a fifty-two week high of $18.76.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%. As a group, equities analysts predict that Sage Therapeutics, Inc. will post -3.52 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Needham & Company LLC reiterated a "hold" rating on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Wedbush reissued a "neutral" rating and issued a $6.00 price objective on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Piper Sandler reduced their price target on shares of Sage Therapeutics from $26.00 to $9.00 and set an "overweight" rating on the stock in a report on Thursday, January 2nd. Stifel Nicolaus cut their price objective on Sage Therapeutics from $10.00 to $6.00 and set a "hold" rating for the company in a research report on Monday, December 16th. Finally, Scotiabank decreased their price objective on Sage Therapeutics from $14.00 to $12.00 and set a "sector outperform" rating on the stock in a research note on Wednesday, February 12th. Three equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and two have given a buy rating to the company. According to MarketBeat.com, Sage Therapeutics has a consensus rating of "Hold" and a consensus target price of $8.81.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.